MAX BioPharma Announces Key Discoveries Regarding Oxysterol Drug Candidates for Targeting Covid-19

Share this article
Share this article
LOS ANGELES, Feb. 2, 2021 /PRNewswire/ -- In collaboration with scientists at the National Institute of Infectious Diseases (NIID) in Tokyo, Japan, MAX BioPharma (www.maxbiopharma.com) scientists have identified new substances with antiviral activity against the novel coronavirus, SARS-CoV-2, the virus that caused the ongoing global COVID-19 pandemic (www.biorxiv.org/content/10.1101/2021.01.31.429001v1).
These new substances, so-called semi-synthetic oxysterols, were derived from a collection of sterol molecules created by MAX BioPharma, as part of its
Oxysterol Therapeutics® platform technology that has produced oxysterol-based drug candidates in other therapeutic indications, including cancer, fibrosis, and bone formation.

Related Keywords

California ,United States ,Japan ,Tokyo ,Koichi Watashi ,Frank Stappenbeck ,Farhad Parhami ,Biopharma Inc ,National Institute Of Infectious Diseases ,National Institute ,Infectious Diseases ,Oxysterol Therapeutics ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,ஜப்பான் ,டோக்கியோ ,தேசிய நிறுவனம் ஆஃப் தொற்று நோய்கள் ,தேசிய நிறுவனம் ,தொற்று நோய்கள் ,